Education
About Us
Working with TipRanks
Follow Us
Idorsia Ltd (CH:IDIA)
:IDIA
Top Page
Idorsia Ltd
(IDIA)
Rating:53Neutral
Price Target:
CHF2.00
▼(-0.99%Downside)
Idorsia Ltd (IDIA) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF454.10M
Dividend YieldN/A
Average Volume (3M)1.30M
Price to Earnings (P/E)―
Beta (1Y)2.77
Revenue Growth11.61%
EPS Growth-356.20%
CountryCH
Employees636
SectorHealthcare
Sector Strength46
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.61
Shares Outstanding225,852,700
10 Day Avg. Volume1,613,109
30 Day Avg. Volume1,300,849
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.24
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF2.20Price Target Upside8.91% Upside
Rating ConsensusHold
Number of Analyst Covering1
Idorsia Ltd Business Overview & Revenue Model
Company DescriptionIdorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
How the Company Makes MoneyIdorsia Ltd generates revenue primarily through the development and commercialization of its pharmaceutical products. The company makes money by bringing its proprietary drugs to market, which involves obtaining regulatory approvals and launching these products globally. Idorsia also enters into strategic partnerships and licensing agreements with other pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties based on product sales. Additionally, the company may receive funding and support from collaborations in research and development efforts, further contributing to its revenue streams. These partnerships help Idorsia to expand its market reach and share the risks and costs associated with drug development.
Idorsia Ltd Earnings Call Summary
Earnings Call Date:Apr 30, 2025
(Q4-2024)
| % Change Since: 71.19%|
Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment Neutral
The earnings call conveyed a balanced sentiment. While Idorsia faced challenges, such as the failed licensing agreement for aprocitentan and financial pressures leading to cost reductions, it also highlighted significant achievements. These included QUVIVIQ's market expansion and sales growth in Europe, Canada, and the US, and strategic financial maneuvers that ensured stability and future funding. Overall, the company is maneuvering through its challenges with a focus on growth and financial stability.Q4-2024 Updates
Positive Updates
QUVIVIQ European and Canadian Market Expansion
QUVIVIQ is now available in nine countries across Europe and Canada, achieving CHF 32 million in net sales in 2024. Sales have shown a steady increase, with significant acceleration in Q4 driven by Germany and France.
US Sales Growth Despite Reduced Investments
QUVIVIQ's US sales grew to over CHF 28 million in 2024 despite a reduction in marketing and selling investments, showing steady growth.
Financial Stability Achieved Through Strategic Measures
Idorsia reduced its R&D commitment by US$100 million and restructured its convertible bonds, securing a new money facility of CHF 150 million, ensuring funds well into 2026.
Aprocitentan Approval and Launch Plans
TRYVIO (aprocitentan) received approval in the US and EU, with preparations for a focused launch in the US ongoing despite previous licensing setbacks.
Negative Updates
Failed Aprocitentan Licensing Agreement
The out-licensing agreement for aprocitentan could not be closed due to the undisclosed party's refusal to pay an exclusivity fee, necessitating alternative partnership strategies.
Financial Challenges and Cost Reductions
Despite strategic financial maneuvers, Idorsia faced significant financial pressures, including a non-GAAP operating loss of CHF 308 million.
Company Guidance
During the call, Idorsia provided guidance for 2025, with the expectation of reaching CHF 110 million in sales for QUVIVIQ, driven by strong performance in the EUCAN region. The company anticipates a non-GAAP EBIT loss of CHF 215 million, a significant improvement from previous years, thanks to cost reductions and a restructuring of their convertible bonds. This includes a CHF 100 million reduction in R&D commitments and a new CHF 150 million funding facility. The US GAAP result is projected at CHF 155 million, incorporating these financial maneuvers. Idorsia remains focused on securing partnerships for their pipeline assets, particularly aprocitentan, to further stabilize and extend their financial runway.Idorsia Ltd Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 70.62M | 152.39M | 97.10M | 35.35M | 71.76M | 23.82M |
| Gross Profit | 38.78M | 145.24M | 90.84M | 17.32M | -309.32M | -414.71M |
| EBITDA | -246.30M | -254.55M | -783.09M | -588.84M | -420.64M | -457.34M |
| Net Income | -296.39M | -297.92M | -827.90M | -634.60M | -445.12M | -494.65M |
Balance Sheet | ||||||
| Total Assets | 1.36B | 500.00M | 904.18M | 1.48B | 1.44B | 1.00B |
| Cash, Cash Equivalents and Short-Term Investments | 811.85M | 157.82M | 476.32M | 1.04B | 1.01B | 743.07M |
| Total Debt | 623.92M | 1.20B | 1.23B | 1.16B | 637.99M | 631.32M |
| Total Liabilities | 805.18M | 1.47B | 1.57B | 1.38B | 849.88M | 839.85M |
| Stockholders Equity | 562.99M | -968.72M | -660.96M | 104.20M | 585.48M | 172.44M |
Cash Flow | ||||||
| Free Cash Flow | -444.30M | -638.69M | -886.17M | -620.83M | -373.95M | -481.03M |
| Operating Cash Flow | -427.18M | -629.30M | -859.11M | -589.89M | -364.67M | -462.04M |
| Investing Cash Flow | 321.40M | 632.61M | 743.90M | -53.26M | -607.13M | -74.81M |
| Financing Cash Flow | -80.00K | -197.00K | 162.31M | 604.15M | 850.08M | 1.33M |
Idorsia Ltd Technical Analysis
Positive
2.02
Price Trends
1.57
Positive
1.28
Positive
1.17
Positive
Market Momentum
0.12
Positive
63.13
Neutral
44.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:IDIA, the sentiment is Positive. The current price of 2.02 is above the 20-day moving average (MA) of 1.95, above the 50-day MA of 1.57, and above the 200-day MA of 1.17, indicating a bullish trend. The MACD of 0.12 indicates Positive momentum. The RSI at 63.13 is Neutral, neither overbought nor oversold. The STOCH value of 44.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:IDIA.
Idorsia Ltd Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | CHF454.10M | ― | ― | 11.61% | -356.20% | ||
51 Neutral | $7.41B | 0.36 | -61.88% | 2.34% | 16.99% | 1.69% | |
| $156.05M | ― | -40.40% | ― | ― | ― | ||
75 Outperform | CHF579.56M | 7.43 | ― | 32.30% | 631.04% | ||
| $170.96M | 11.40 | ― | ― | ― | |||
| $193.16M | 2.70 | -93.91% | ― | ― | ― | ||
| CHF113.40M | 3.29 | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
CH:IDIA
Idorsia Ltd
2.02
-0.08
-3.81%
MLLCF
Molecular Partners AG
4.22
-5.68
-57.37%
CH:BSLN
Basilea Pharmaceutica
47.60
8.10
20.51%
NWPHF
Newron Pharmaceuticals SpA
9.36
-2.64
-22.00%
SPHDF
Santhera Pharmaceuticals Holding
14.82
3.12
26.67%
CH:XLS
Xlife Sciences Ltd.
19.75
-9.25
-31.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.